"The U.S. Food and Drug Administration today approved a new use for Jakafi (ruxolitinib) to treat patients with polycythemia vera, a chronic type of bone marrow disease. Jakafi is the first drug approved by the FDA for this condition.
- GAMUNEX (immune globulin intravenous (human) 10%) is contraindicated in individuals with acute severe hypersensitivity reactions to Immune Globulin (Human).
- GAMUNEX (immune globulin intravenous (human) 10%) contains trace amounts of IgA. It is contraindicated in IgA deficient patients with antibodies against IgA and history of hypersensitivity. (See DESCRIPTION)
Last reviewed on RxList: 10/2/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Gamunex Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.